Human Vaccines | Emerging Technologies in Design and Development. Dieser Artikel ist nicht verfügbar.Human Vaccines | Emerging Technologies in Design and Development

Human Vaccines: Emerging Technologies in Design and Development discusses the advances in molecular biology, biophysics, and informatics-among other disciplines-that have provided scientists with the tools to create new vaccines against emerging and re-emerging pathogens. For example, the virus-like particle technologies that led to licensing of highly efficacious HPV vaccines have only come into full realization in the last 10 years. Their success has, in turn, accelerated the pace with which nanoparticle vaccines are being developed Given the rapidity with which the field is changing and the absence of any text documenting this change, there is a need for a resource that surveys these new vaccine technologies, assesses their potential, and describes their applications. This book provides that resource and complements traditional vaccinology books, but also serves as an excellent standalone for researchers and students with basic knowledge in immunology.

Prof. Modjarrad is Adjunct Assistant Professor of Medicine at the Johns Hopkins University School of Medicine, Attending on infectious diseases consult service at the main hospital 1 month per year. Responsible for teaching residents and fellows. He was awarded with the following grants: 1. Vanderbilt Infection Pathogenesis and Epidemiology Research Training Program, $233,075, 2011-2012,

2. Vanderbilt International Office Exchange Grant, $15,000, 2008-2009.

3. EGPAF Research Grant (PG-51368), $280,000, 2003-2005.

4. U.S. Department of Defense, $15,000, 2003-2004.

5. National Institutes of Health, Fogarty International Research Collaborative Award (5R03TW005929-02), $100,000, 2002-2004.

He is the Co-Editor for the medical polymers series, beginning with the Handbook of Polymer Applications in Medicine and Medical Devices, first volume published in December 2013 (Williams Andrews).

Wayne C. Koff, PhD, is the founding President & CEO of the Human Vaccines Project (April 2016-present), a public-private partnership with the goal of decoding the human immune system to accelerate development of vaccines and immunotherapies for major infectious diseases and cancers. Prior to joining the Project, Dr Koff served as Chief Scientific Officer & Senior Vice President, Research & Development at the International AIDS Vaccine Initiative (IAVI) in New York City (1999-2016), leading IAVI’s research and development program. At IAVI, Dr. Koff’s accomplishments included: Developing multiple HIV vaccines through clinical trials; Establishing state of the art laboratories in the US, Europe, India and Africa; Conducting the first HIV vaccine trials in India, Kenya, and Rwanda; Establishing the Neutralizing Antibody Consortium which identified new, broad and potent neutralizing antibodies against HIV that led to the discovery of novel targets for vaccine design; and established a clinical research network in Africa that has conducted seminal studies on HIV pathogenesis, incidence, and acute infection. Dr. Koff served as Vice President, Vaccine Research and Development (1992-1998), at United Biomedical, Inc. (UBI), where he was responsible for its vaccine R&D program. During his tenure at UBI, the company conducted the first AIDS vaccine clinical trials in the developing countries of the People's Republic of China, Thailand, and Brazil. He served as Chief of the Vaccine Research and Development Branch (1988-1992), Division of AIDS, at the National Institute of Allergy and Infectious Diseases (NIAID), where he led the team that established the preclinical and clinical AIDS vaccine development programs for the National Institutes of Health (NIH). He received his B.A. from Washington University and his Ph.D. from Baylor College of Medicine. Dr. Koff has published more than 100 scientific papers and edited eight books on vaccine development. An internationally recognized viral immunologist in the field of AIDS vaccine research and development, he has been twice honored by the U.S. Department of Health and Human Services with the Special Act of Service Award for developing innovative strategies for accelerating global efforts in AIDS vaccine development.